Annexin Pharmaceuticals AB Logo

Annexin Pharmaceuticals AB

ANNX | ST

Overview

Corporate Details

ISIN(s):
SE0009664154
LEI:
5493000JP703HGPJEX27
Country:
Sweden
Address:
KAMMAKARGATAN 48, 111 60 Stockholm
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Annexin Pharmaceuticals AB is a clinical-stage biotechnology company focused on developing therapies centered on the human protein Annexin A5. The company's lead drug candidate, ANXV, is a recombinant form of Annexin A5 designed to target the lipid phosphatidylserine (PS), which is exposed on the surface of stressed and damaged cells. By binding to PS, ANXV aims to create a protective shield that counteracts cellular stress, modulates immune responses, and repairs tissue injury. The company is primarily investigating ANXV's therapeutic potential in ophthalmology, specifically for Retinal Vein Occlusion (RVO), where it is positioned as a potential First-in-Class treatment, and in oncology. The drug's unique mechanism of action offers a novel approach for various diseases where PS exposure is a contributing factor.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Annexin Pharmaceuticals AB. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Annexin Pharmaceuticals AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Annexin Pharmaceuticals AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Medicofarma Biotech Spolka Akcyjna Logo
Biotech R&D firm developing novel drugs, devices, and therapies with a focus on oncology.
Poland MDB
Medigene AG Logo
An immuno-oncology platform creating T cell receptor (TCR)-guided therapies to treat cancer.
Germany MDG1
MedinCell S.A. Logo
Develops and licenses long-acting injectable therapies using proprietary technology.
France MEDCL
Medivir Logo
Clinical-stage pharma firm developing tumor-directed therapies for high-need cancer patients.
Sweden MVIR
Mendus Logo
Developing immunotherapies using dendritic cells to prevent recurrence of AML & ovarian cancer.
Sweden IMMU
Merck KGaA Logo United States of America 6MK
Sweden MBOLIC
Milton Essex Spolka Akcyjna Logo
Develops AI-powered, non-invasive systems for allergy diagnostics & personalized medicine.
Poland MTN
Modus Therapeutics Holding AB Logo
Clinical-stage biotech developing sevuparin for sepsis, septic shock, and inflammation.
Sweden MODTX
Molecular Partners AG Logo
Pioneering DARPin protein drugs for complex diseases in oncology and virology.
Switzerland MOLN